Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials

Data source: Bayside Health Alfred Powertrials list of active trials
Last updated: 9 October 2026

Clear filter
681 clinical trials found
Clinical trials

INCB161734-303 / DAWN-303

A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma [DAWN-303] (NCT07522073)

The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
Currently recruiting

INDEX-AF

The role of pharmacological heart failure therapy in LV recovery following INDEX catheter ablation for atrial fibrillation [AF] induced cardiomyopathy - the INDEX-AF Study (ACTRN12625000464460)

A randomised control clinical trial to explore whether patients with AF-induced cardiomyopathy undergoing catheter ablation can avoid anti-heart failure pharmacotherapy. Patients will be randomised to receive anti-heart failure pharmacotherapy (control) versus monitoring without anti-heart failure pharmacotherapy (intervention). The primary outcome will be change in left ventricular ejection fraction from baseline.

Currently recruiting

INNOVATE

A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons with HIV-1 (NCT07202546)

This clinical study is testing a new medication, VH4524184, to see if it can effectively treat HIV-1 in adults who have never received treatment for their infection. The study is comparing two different doses of VH4524184, each taken with the medications emtricitabine and tenofovir alafenamide (FTC/TAF), to a standard HIV treatment called dolutegravir and lamivudine (DTG/3TC). The purpose of the study is to provide data on the long-term antiviral activity of the VH4524184 and provide information regarding dosing formulation for further evaluations. 

No longer recruiting

IPL Donor Site Scar Trial

Effect of Intense Pulsed Light (IPL) on Vascularity and Hypertrophic Scar Development in Burn Donor Sites: A Randomised Controlled Trial Using Objective Imaging with the Antera 3D System

This prospective, intra-subject controlled trial will evaluate the effect of Intense Pulsed Light (IPL) therapy on vascularity and scar outcomes in 20 adults with split-thickness skin graft donor sites at increased risk of hypertrophic scarring. Each participant will have two comparable donor-site areas, with one receiving IPL plus standard scar management and the other receiving standard scar management alone as an intra-subject control. IPL treatment will commence 12 weeks after complete epithelialisation, with three treatment sessions at eight-week intervals. Scar vascularity will be objectively assessed using Antera 3D imaging, with secondary outcomes including scar quality using POSAS 3.0 and health-related quality of life using the EQ-5D. Participants will be followed for 12 months following the final treatment.
Coming soon

IPSEN Meranti

A multicentre, randomised, double-blind, placebo-controlled, dose escalation and dose finding phase II study to evaluate the safety and efficacy of IPN10200 in the prevention of episodic or chronic migraine in adults (NCT06625060)

The purpose of this study is to investigate the safety and effectiveness of IPN10200, in participants living with migraines. The information gathered from this study will contribute to our understanding of how this study treatment may benefit individuals suffering from migraines. Participants will be assigned the study drug or placebo. Following the confirmation of safety in Step 1 by the DMC, up to two doses of IPN10200 will be compared against placebo in parallel groups in Step 2. 
Participants who meet all study criteria will be randomly assigned to one of three intervention groups: Dose A, Dose B or a placebo. Each participant will be in the study for 40 to 44 weeks including a screening period of 6 weeks (± 2 weeks).
Participants who fulfill all study criteria, will be included and will receive the study treatment at Day 1 (D1), followed by a follow up period of 36 weeks. All the participants will have to attend 7 onsite visits during the study including Screening visit, Day 1, and follow up visits at study site. Participants will also have remote visits (about 7 phone calls in total).

Currently recruiting